Review articleBreast cancer

Breast cancer statistics 2024

CA A Cancer J Clinicians · 2024Not stated in the abstract

Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. CA A Cancer J Clinicians. 2024. 74:477-495

Study type: Review article
Study name: ACS Breast Cancer Statistics 2024
Design: Biennial statistical report (update) of the American Cancer Society based on incidence and mortality data from the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC)
Sample size: Not stated in the abstract
Source: CA A Cancer J Clinicians · 2024

In plain words

This report shows that in the United States the number of women diagnosed with breast cancer has risen slightly, but deaths from the disease fell by about 44% between 1989 and 2022. This progress has not been the same for every group: for example, Black women are diagnosed less often but are more likely to die of the disease. Better and fairer access to screening and high-quality treatment can help reduce these gaps. These figures are for the United States.

Key results

Increase of 1% per year

Trend in breast cancer incidence (2012 to 2021)

Largely confined to localised-stage and hormone receptor-positive disease

1.4% vs 0.7% per year

Increase in incidence in women under 50 vs 50 and older

Overall; significant only in White women

2.7% and 2.5% per year

Increase in incidence in Asian American/Pacific Islander women (under 50 and 50 and older)

The fastest increase in both age groups

57.4 per 100,000 in 2000 vs 86.3 per 100,000 in 2021

Incidence rate in young Asian American/Pacific Islander women

Second lowest in 2000; in 2021 the highest rate alongside White women (86.4 per 100,000) and higher than Black women (81.5 per 100,000)

44%

Decline in breast cancer mortality rate (1989 to 2022)

Equivalent to 517,900 fewer breast cancer deaths

Unchanged since 1990

Mortality in American Indian/Alaska Native women

38% higher

Mortality in Black vs White women

Despite 5% lower incidence

58% vs 68%

Diagnosis at localised stage: Black vs White women

10% lower likelihood of diagnosis at a localised stage in Black women

Study population

Women with breast cancer in the United States; the data are based on high-quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Further details are given in the full text of the paper.

Endpoints

Trends in breast cancer incidence (2012 to 2021) and mortality (1989 to 2022) by age, race/ethnicity, stage and molecular subtype (hormone receptor, triple-negative), as well as survival disparities.

Safety and side effects

In keeping with the nature of the paper (a statistical report), treatment adverse events were not examined.

Clinical significance and place in guidelines

This paper is a statistical report, not an interventional study, so it makes no new treatment recommendations. According to the abstract, the findings emphasise the importance of reducing racial, ethnic and social disparities by improving representation in clinical trials and access to high-quality screening and treatment. The data relate to the US population and their applicability to other populations needs to be assessed.

Limitations

The abstract does not mention the study's limitations. The data relate to the United States, and incidence and mortality trends may differ in other countries. Further details are available in the full text of the paper.

Original article (DOI)PubMed

This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.